Quote this publication Share Print

AOTAL (acamprosate), alcohol dependence products

Opinions on drugs - Posted on Jan 17 2019

Reason for request

Renewal of inclusion

High clinical benefit in the management of alcohol dependent patients maintained


  • AOTAL, ESPERAL and REVIA are used to maintain abstinence in alcohol-dependent patients in the context of comprehensive management with psychological counselling.

  • AOTAL and REVIA are first-line treatments, while ESPERAL is a second-line treatment due to its antabuse effects.

  • A meta-analysis failed to show any significant differences between acamprosate and naltrexone in terms of abstinence and relapse.



Clinical Benefit



Therapeutic use